| Literature DB >> 31814981 |
Maiko Kitajima1, Kasumi Mikami1, Yuka Noto1, Chieko Itaki1, Yasuyo Fukushi2, Yoshiko Hirota3, Yasushi Mariya2, Megumi Tsushima1, Keiichi Kattou3, Tomohiro Osanai1.
Abstract
Assessment of skin condition is necessary for providing advice regarding skin self-care to patients with breast cancer who have undergone radiation therapy. Acute and chronic phases of radiodermatitis were analyzed in patients using objective assessment tools in the present study. A total of 18 women who received radiation therapy for breast cancer were enrolled in the present study and their skin surface temperature (SST), hydration level of the skin surface (HL), melanin intensity (MI) and erythema intensity (EI) were measured prior to radiation therapy and six months thereafter. Furthermore, skin condition was assessed using the Common Terminology Criteria for Adverse Events (CTCAE). EI and MI levels at the irradiated site peaked upon the completion of radiation therapy and declined to baseline at 6 months. In contrast, SST levels were elevated at the irradiated site during radiation therapy (P<0.05) and plateaued after its completion. The same parameters in non-irradiated control sites remained unchanged during the study period. HL reached the minimum in irradiated and non-irradiated sites upon completion of radiation therapy. Although HL returned to baseline in the non-irradiated site 6 months after radiation therapy, it remained low in the irradiated site. No relationship between the CTCAE and EI level was observed. In conclusion, the present study demonstrated that objective assessment tools, including SST and EI levels, were useful for assessing skin condition during radiodermatitis. The combination of the CTCAE and objective assessment tools will enable a more accurate assessment of radiodermatitis.Entities:
Keywords: breast cancer; erythema intensity; hydration level; radiodarmatitis; skin surface temperature
Year: 2019 PMID: 31814981 PMCID: PMC6888041 DOI: 10.3892/mco.2019.1948
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450